Incyte Corporation
Incyte Reports 2025 First Quarter Financial Results and Clinical Updates
Summary
Incyte Corporation announced its 2025 first quarter financial results, showing total revenues of $1.053 billion, a 20% increase year-over-year. Net product revenues grew by 26%, driven by increased demand for Jakafi and Opzelura. Jakafi net product revenues were $709 million, and Opzelura net product revenues were $119 million. Incyte also provided updates on its clinical development programs, including positive results from studies of povorcitinib in hidradenitis suppurativa and chronic spontaneous urticaria. The company raised its full-year 2025 Jakafi revenue guidance to a new range of $2.950 - $3.000 billion.
Profitelligence Alerts
Get alerts for INCY
Be first to know when Incyte Corporation files with the SEC.
Filing Categories
Exhibits (1)
Advertisement
About Incyte Corporation
Incyte Corporation is a biopharmaceutical company dedicated to the discovery, development, and commercialization of innovative therapeutics. With a focus on oncology and inflammation, Incyte aims to address significant unmet medical needs through its robust portfolio of proprietary compounds. The company's flagship product, a therapeutic for certain types of blood cancers, underscores its pivotal role in cancer treatment paradigms. Incyte also invests heavily in research and development, maintaining a pipeline of next-generation treatments in various stages of clinical trials. Having established strategic partnerships with leading global pharmaceutical companies, Incyte leverages collaborative efforts to enhance its research capabilities and market presence. Headquartered in Wilmington, Delaware, Incyte Corporation is a key player in the biopharmaceutical sector, significantly contributing to advancements in medical science and patient care through its commitment to innovation and therapeutic excellence.
Official SEC Documents
Advertisement